RhumbLine Advisers’s Carisma Therapeutics CARM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-8,387
| Closed | -$12.7K | – | 4219 |
|
|
2024
Q2 | $12.7K | Sell |
8,387
-26,701
| -76% | -$40.6K | ﹤0.01% | 3946 |
|
|
2024
Q1 | $79.6K | Buy |
35,088
+735
| +2% | +$1.67K | ﹤0.01% | 3513 |
|
|
2023
Q4 | $101K | Sell |
34,353
-10
| -0% | -$29 | ﹤0.01% | 3445 |
|
|
2023
Q3 | $145K | Buy |
34,363
+2,797
| +9% | +$11.8K | ﹤0.01% | 3323 |
|
|
2023
Q2 | $277K | Buy |
+31,566
| New | +$277K | ﹤0.01% | 3063 |
|
|
2022
Q2 | – | Sell |
-7,480
| Closed | -$90K | – | 3114 |
|
|
2022
Q1 | $90K | Buy |
7,480
+529
| +8% | +$6.37K | ﹤0.01% | 2903 |
|
|
2021
Q4 | $113K | Sell |
6,951
-171
| -2% | -$2.78K | ﹤0.01% | 2925 |
|
|
2021
Q3 | $113K | Buy |
7,122
+695
| +11% | +$11K | ﹤0.01% | 2982 |
|
|
2021
Q2 | $594K | Buy |
+6,427
| New | +$594K | ﹤0.01% | 2489 |
|